黑石生命科学公司(Blackstone Life Sciences)同意向默克公司提供7亿美元,支持其研发一种名为sacituzumab tirumotecan的实验性抗癌药物。默克公司目前正在对该药进行15项三期临床试验,涉及6种肿瘤类型,包括乳腺癌、子宫内膜癌和肺癌。根据协议,黑石将有资格获得该药物的部分特许权使用费,默克将保留对该药开发、生产和商业化的决策权和控制权。
黑石生命科学公司(Blackstone Life Sciences)同意向默克公司提供7亿美元,支持其研发一种名为sacituzumab tirumotecan的实验性抗癌药物。默克公司目前正在对该药进行15项三期临床试验,涉及6种肿瘤类型,包括乳腺癌、子宫内膜癌和肺癌。根据协议,黑石将有资格获得该药物的部分特许权使用费,默克将保留对该药开发、生产和商业化的决策权和控制权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.